Research Project
Grant-in-Aid for Scientific Research (A)
We have been developing MHC-restricted cell therapy using brain-tumor specific antigen and its chemicals. At first we identified X-linked X-linked inhibitor of apoptosis protein (XIAP), Aurora-B, c-Jun N-terminal kinase (JNK) and Fas as brain tumor-specific or associated antigens. Thereafter we designed their chemicals using methods of structure-based drug design or genome-information drug design, confirming their biological activities in cultured human glioma cells. Until now we operated genetic medicines in Japan for over 20 years and provided medical services to patients with formidable diseases such as malignant glioma and malignant melanoma. The results were succeeded to The Center for Genetic and Regenerative Medicine (CGRM) in our Hospital, which is an institute to put advanced medicine into practice in Nagoya University Hospital. There we are responsible for process development, validation, and GMP (Good Manufacturing Practice) production of a broad range of novel cell and gene therapies including dendritic cell vaccines, antigen-specific CTLs (cytotoxic T lymphocytes), plasmid DNA, liposomes with plasmid DNA, and bio-materials for regenerative medicine, in support of some clinical trials. In 2006 this CGRM gained ISO (International Organization for Standardization) 9001:2000 and 13485:2003 Accreditation. We became the first academic institute in Japan to achieve the ISO Quality. We opened clinical trials for patients with recurrent malignant glioma using MHC-restricted cells against some brain-tumor specific or associated antigen
All 2007 2006 2005 2004
All Journal Article (110 results)
J Neuro-Oncol. (in press)
Int J Oncol (in press)
Cancer Sci. (in press)
Int. Immunol. (in press)
Biomedical Research. 27
Pages: 1-9
Bioorg. Med. Chem. 14
Pages: 4217-4226
J Neuro-Oncol. (In press)
Int J Oncol (In press)
Cancer Sci (In press)
Int. Immunol. (In press)
Int. Immunol (In press)
Neuro-Oncol. 8(2)
Pages: 137-144
J Neuro-Oncol. 77(3)
Pages: 285-289
Minimally Invasive Neurosurgery and Multidisciplinary Neurotraumatology.
Pages: 1191-1123
Cancer Sci 97
Pages: 920-927
Cancer Sci. 97
Pages: 1236-1241
Int J Oncol. 28
Pages: 1089-1098
Cancer Res. 66
Pages: 1809-1817
Int Immunol. 18
Pages: 425-434
Pages: 139-147
Chemistry 12
Pages: 9066-9080
Biochem. Biophys. Res. Commun. 345
Pages: 560-567
Apoptosis 11
Pages: 555-562
Arthritis Rheum. 54
Pages: 473-481
J. Neurochem. 96
Pages: 533-540
Pages: 137-44
Springer-Verlag (Tokyo)
Pages: 1191-123
Pages: 1231-1241
Int J Oncol 28
Biomedical Research 27
Cancer Res 66
Int Immunol 18
Res. Commun. 345
Med. Chem. 14
Cancer Res 65
Pages: 7573-7579
Immunol Lett 101
Pages: 95-103
Blood 106
Pages: 470-476
Int J Oncol 26
Pages: 679-684
Apoptosis 10
Pages: 1121-1130
Biochem. J 392
Pages: 511-517
Pages: 471-480
Biochem. Pharmacol 70
Pages: 37-46
Pages: 323-329
Clin. Exp. Immunol. 139
Pages: 268-278
Biochem. Biophys. Res. Commun. 327
Pages: 76-83
Autoimmunity 38
Pages: 369-375
Cancer Res. 65817
Biochem. J. 392
Pharmacol. 70
Biophys. Res. Commun. 327
Cancer Sci 95(11)
Pages: 858-865
J Neurosurg 101
Pages: 1012-1017
Int J Cancer 111
Pages: 777-782
Annals of Cancer Research and Therapy 12
Pages: 71-86
Cancer Res 64
Pages: 8754-8760
Cancer Sci 95
Pages: 697-703
Int Immunol 16
Pages: 811-817
Biochem Biophys Res Commun 314
Pages: 468-475
Pages: 1497-1505
Pages: 1490-1495
Immunol Lett 93
Pages: 17-25
Pages: 386-390
Biochem. Biophys. Res. Commun. 325
Pages: 1292-1297
Biochem. Biophys. Res. Commun. 321
Pages: 355-363
Biol. Pharm. Bull. 27
Pages: 968-973
Genomics 84
Pages: 95-105
Cell Death Differ. 11
Pages: 1112-1120
BMC Pharmacol. 4
Pages: 7
Cell Tissue Res. 316
Pages: 403-407
Exp. Gerontol. 39
Pages: 195-202
Sci. STKE
Pages: PL7
Hum Gene Ther 15
Pages: 77-86
JNS 101
Res. Commun. 325
Res. Commun. 321
Pharm. Bull. 27
Gerontol. 39
Sci. STKE. 2004
Human gene therapy 15